CD274 and neoplasm: Finally, the results showed that comorbidities (adjusted OR = 0.16), PD-L1 expression of pre-NCIO (adjusted OR = 9.66), pembrolizumab/nab-paclitaxel–based regimens (adjusted OR = 4.92), and tumor regression rate (adjusted OR = 12.33) were independently associated with pCR (all P < 0.05).